FVIII-Chulalongkorn University-Hemophilia A

FVIII-Chulalongkorn University-Hemophilia A refers to the Factor VIII (FVIII) replacement therapy program and associated therapeutic candidates developed or clinically evaluated by Chulalongkorn University for the treatment of Hemophilia A. The initiative encompasses both the development of locally produced recombinant FVIII to improve treatment accessibility in Thailand and clinical research into optimizing prophylaxis using standard half-life (SHL) and extended half-life (EHL) FVIII concentrates. A primary focus of the university's work is the implementation of pharmacokinetic (PK)-guided dosing strategies, utilizing tools such as the MyPKFiT system to individualize treatment. This approach aims to maintain protective FVIII trough levels (typically >1%), thereby reducing annual bleeding rates (ABR) and improving long-term joint health outcomes in patients with severe Hemophilia A compared to traditional weight-based dosing regimens.

Other names

Factor VIIIFVIIIExtended half-life FVIIIStandard half-life FVIIIEHL FVIIISHL FVIII